(Q33487687)

27 July 2017

title

A phase I study of sulofenur in refractory pediatric malignant solid tumors (English)

1 reference

27 July 2017

Pratt CB

1

1 reference

27 July 2017

Bowman LC

2

1 reference

27 July 2017

Marina N

3

1 reference

27 July 2017

Pappo A

4

1 reference

27 July 2017

Avery L

5

1 reference

27 July 2017

Luo X

6

1 reference

27 July 2017

Meyer WH

7

1 reference

27 July 2017

publication date

1 January 1995

1 reference

Investigational New Drugs

27 July 2017

published in

1 reference

27 July 2017

volume

13

1 reference

27 July 2017

issue

1

1 reference

27 July 2017

page(s)

63-66

1 reference

https://scigraph.springernature.com/pub.10.1007/bf02614222

27 July 2017

exact match

0 references

cites work

Phase II trial of the novel sulphonylurea sulofenur in advanced breast cancer

1 reference

12 December 2020

Phase II study of sulofenur (LY 186641) in untreated patients with extensive small cell lung cancer

1 reference

12 December 2020

A phase II study of sulofenur (LY186641) in gastric cancer

1 reference

12 December 2020

Effects of diarylsulfonylurea antitumor agents on the function of mitochondria isolated from rat liver and GC3/c1 cells

1 reference

12 December 2020

Phase I clinical study of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641)

1 reference

12 December 2020

Evaluation of N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)-urea against xenografts of pediatric rhabdomyosarcoma.

1 reference

12 December 2020

Phase II study of sulofenur (LY 186641). A novel antineoplastic agent in advanced non-small cell lung cancer

1 reference

12 December 2020

Clinical pharmacology of a novel diarylsulfonylurea anticancer agent

1 reference

12 December 2020

A phase II study of sulofenur, a novel sulfonylurea, in recurrent epithelial ovarian cancer.

1 reference

12 December 2020

Evidence for mitochondrial localization of N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl)urea in human colon adenocarcinoma cells

1 reference

12 December 2020

Kinetics of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641) in humans

1 reference

12 December 2020

Phase II study of sulofenur (LY186641) in measurable metastatic renal cancer

1 reference

12 December 2020

Evaluation of the methemoglobinemia associated with sulofenur

1 reference

12 December 2020

Phase I trial of sulofenur (LY186641) given orally on a daily x 21 schedule

1 reference

12 December 2020

Effect of antitumor diarylsulfonylureas on in vivo and in vitro mitochondrial structure and functions.

1 reference

12 December 2020

Sulfonylureas: a new class of cancer chemotherapeutic agents

1 reference

12 December 2020

Phase II trial of LY 186641 in advanced renal cancer

1 reference

12 December 2020

Phase II evaluation of the sulfonylurea LY186,641 in men with hormone independent metastatic prostate cancer

1 reference

12 December 2020

Proliferation-dependent and -independent cytotoxicity by antitumor diarylsulfonylureas. Indication of multiple mechanisms of drug action.

1 reference

12 December 2020

N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)urea, a novel agent equally cytotoxic to nonproliferating human colon adenocarcinoma cells

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02614222

1 reference

Dimensions Publication ID

27 July 2017

1015184877

0 references

1 reference